Shire's Vyvanse (lisdexamfetamine dimesylate) CII is now available in a chewable tablet formulation, making it the only Attention-Deficit/Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED) treatment available in five administration options.
“Vyvanse chewable tablets will offer an option to patients who may need an alternate form of this medication,” Shire U.S. Neuroscience Franchise head Mark Rus said. “Our primary responsibility is to our patients and, with the new Vyvanse chewable formulation, we offer physicians an option to help patients who may have difficulty swallowing or would prefer a chewable tablet to help manage their condition.”
Vyvanse is indicated for treating patients with ADHD who are 6 years old or older as well as adults with moderate to severe BED. The chewable formulation was approved by the FDA in January 2017 and is now available in select pharmacies in the U.S. in 10, 20, 30, 40, 50 and 60mg tablets.
Vyvanse chewable tablets are for oral administration only and carry the same dosing as the drug’s capsule formulation. Vyvanse must betaken as prescribed and patients should follow the instructions given in the Medication Guide.